Literature DB >> 2003991

Arteriovenous shunting in patients with colorectal liver metastases.

J A Goldberg1, J A Thomson, G McCurrach, J H Anderson, N Willmott, R G Bessent, J H McKillop, C S McArdle.   

Abstract

The outlook for patients with colorectal liver metastases is poor. Microspheres have been combined with cytotoxics and administered via the hepatic artery in an attempt to improve tumour drug exposure within the liver. However, it has been suggested that arteriovenous connections might occur in association with intrahepatic tumours causing loss of regional advantage, and that the administration of microspheres further exacerbates arteriovenous shunting. In seven patients with colorectal liver metastases, base-line shunting was measured using a tracer quantity of radio-labelled albumin microspheres. The shunted fraction of a 'therapeutic quantity' of microspheres was subsequently measured in the same group of patients using albumin microspheres carrying a different radio-label. Base-line shunt for 0.5 x 10(6) microspheres was found to be 2.2 +/- 1.8% (mean +/- s.d.); the percentage shunt of a therapeutic quantity (40-80 x 10(6)) of microspheres was 3.0 +/- 0.8%. We conclude that arteriovenous shunting in patients with colorectal liver metastases is minimal, and is not significantly increased by the administration of therapeutic quantity of microspheres during regional chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2003991      PMCID: PMC1971851          DOI: 10.1038/bjc.1991.109

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  Biodegradation rate of embolized protein microspheres in lung, liver and kidney of rats.

Authors:  N Willmott; Y Chen; J Goldberg; C Mcardle; A T Florence
Journal:  J Pharm Pharmacol       Date:  1989-07       Impact factor: 3.765

2.  Cytotoxic-loaded albumin microspheres: a novel approach to regional chemotherapy.

Authors:  C S McArdle; H Lewi; D Hansell; D J Kerr; J McKillop; N Willmott
Journal:  Br J Surg       Date:  1988-02       Impact factor: 6.939

3.  Improved regional selectivity of hepatic arterial BCNU with degradable microspheres.

Authors:  S Dakhil; W Ensminger; K Cho; J Niederhuber; K Doan; R Wheeler
Journal:  Cancer       Date:  1982-08-15       Impact factor: 6.860

4.  Quantitative hepatic arterial perfusion scintigraphy and starch microspheres in cancer chemotherapy.

Authors:  H A Ziessman; J H Thrall; J W Gyves; W D Ensminger; J E Niederhuber; M Tuscan; S Walker
Journal:  J Nucl Med       Date:  1983-10       Impact factor: 10.057

5.  Phase I study of hepatic arterial degradable starch microspheres and mitomycin.

Authors:  W D Ensminger; J W Gyves; P Stetson; S Walker-Andrews
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

6.  Arteriovenous shunting of microspheres in patients with colorectal liver metastases: errors in assessment due to free pertechnetate, and the effect of angiotensin II.

Authors:  J A Goldberg; M S Bradnam; D J Kerr; D M Haughton; J H McKillop; R G Bessent; N Willmott; C S McArdle; W D George
Journal:  Nucl Med Commun       Date:  1987-12       Impact factor: 1.690

7.  Adriamycin-loaded albumin microspheres: preparation, in vivo distribution and release in the rat.

Authors:  N Willmott; J Cummings; J F Stuart; A T Florence
Journal:  Biopharm Drug Dispos       Date:  1985 Jan-Mar       Impact factor: 1.627

8.  Effects of intra-arterially infused biodegradable microspheres containing mitomycin C.

Authors:  S Fujimoto; M Miyazaki; F Endoh; O Takahashi; R D Shrestha; K Okui; Y Morimoto; K Terao
Journal:  Cancer       Date:  1985-02-01       Impact factor: 6.860

9.  Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases.

Authors:  J A Goldberg; D J Kerr; N Willmott; J H McKillop; C S McArdle
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

10.  Arterial chemoembolization with cisplatin microcapsules.

Authors:  Y Okamoto; A Konno; K Togawa; T Kato; Y Tamakawa; Y Amano
Journal:  Br J Cancer       Date:  1986-03       Impact factor: 7.640

View more
  3 in total

Review 1.  Clinical pharmacokinetic advantages of new drug delivery methods for the treatment of liver tumours.

Authors:  J H Anderson; H W Warren; C S McArdle
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 2.  Hepatic arterial chemotherapy for metastatic colorectal carcinoma.

Authors:  P G de Takats; D J Kerr; C J Poole; H W Warren; C S McArdle
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

3.  Characterisation of tumour blood flow using a 'tissue-isolated' preparation.

Authors:  G M Tozer; K M Shaffi; V E Prise; V J Cunningham
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.